
Ill winds are blowing for Labour's 2030 deadline for clean energy
Neso's £200bn plan, detailing a rapid rollout of offshore wind, onshore wind, solar farms plus a major upgrade of the electricity grid, was adopted virtually unchanged by the government at the end of last year.
Now something has gone wrong. Ørsted, the Danish developer, has stopped work on one of the world's biggest offshore wind projects, Hornsea 4 off the Yorkshire coast. It can't make the numbers add up. It would rather write off £400m-plus in impairments and the cost of cancelling orders with suppliers.
One windfarm alone, you might think, cannot put a serious dent in the overall 2030 project. Up to a point, that's true. There is time to catch up and Neso's report spoke about 'some flexibilities at the margin' when it came to technologies – extra solar could substitute for a shortfall in wind. In any case, the precise 2030 target for installed offshore wind capacity hasn't yet been nailed down; it is between 43 and 51 gigawatts depending on how many carbon capture sites and green hydrogen plants end up being built.
Yet the basic point remains: Hornsea 4 is a bad one to lose. It is a 2.4GW project – vast, in other words – and, whatever fiddles can be made around the edges, Neso was always clear that offshore wind would be 'the bedrock' of a cleaned-up system, providing more than half of Great Britain's generation. If the government already needed to secure 20GW of offshore wind in the next couple of years, which is roughly how the blurry maths works out, the requirement has gone up by 10% overnight. A demanding deadline has become even more demanding.
Ed Miliband, the energy secretary, would be within his rights to be furious with Ørsted. The company grumbled about supply chain costs, interest rates and 'adverse macroeconomic developments', but no other offshore developer that won a price contract in last year's auction round (AR6) has dropped its project. It rather looks as if Ørsted bid too aggressively, was distracted by its woes in the US, or failed to agree contracts with suppliers in time, or all three. Hornsea's place in the AR6 auction could have been taken by a disappointed bidder, such as RWE.
Alternatively, Ørsted may be engaged in brinkmanship, a question asked by Barclays' energy analyst. The headline on the company's announcement said Hornsea 4 would be discontinued 'in its current form', seemingly suggesting it would be back in the game if only the government would cough up more than the £58.87 per megawatt hour at which the AR6 auction settled for offshore wind projects. The energy department's comment that it would 'work with Ørsted to get Hornsea 4 back on track' hinted it may indeed be up for renegotiation. If so, those entitled to be furious would be other AR6 developers who are delivering what they agreed at the original price.
Whatever happens at Hornsea 4, the timing of Ørsted's move sends a bad price signal (from the point of view of the government and consumers) for AR7, the renewables auction due this summer. The background noise is already complaints from companies about ministerial dithering over whether to switch to a zonal pricing system for electricity; and, if zonal is rejected, what does the alternative of a reformed national market look like? The information is critical to anybody planning to invest billions in generating capacity.
skip past newsletter promotion
Sign up to Business Today
Get set for the working day – we'll point you to all the business news and analysis you need every morning
Privacy Notice: Newsletters may contain info about charities, online ads, and content funded by outside parties. For more information see our Privacy Policy. We use Google reCaptcha to protect our website and the Google Privacy Policy and Terms of Service apply.
after newsletter promotion
The zonal uncertainty had probably already added upwards pressure on prices for new offshore wind capacity. Now Ørsted has created a catch-up problem, while advertising worries over costs. Energy analysts reckon the government will be lucky to contain inflation in offshore wind contracts to 10%. It could be higher.
Therein lies one problem with setting a rigid 2030 deadline. You can end up paying extra to get the job done on time, or renegotiating major projects from a position of weakness. We'll reserve judgment until we see the actual prices in the AR7 auction. But 2030, which many energy executives never thought was do-able anyway, already looks too tight for comfort.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Barcelona sporting director sends clear message to defensive outcast
Barcelona are facing a race against time as they look to not only register the new signings but also get the Camp Nou prepared for September matches. In the midst of all that, the club are facing a financial crunch once again and desperately require fresh sales in order to balance the books and return to the 1:1. Following the departures of Pablo Torre, Pau Victor and Ansu Fati, the next player in line to leave Barcelona this summer is Andreas Christensen. But the Dane, despite being considered a benchwarmer, has appeared hesitant to leave Barcelona. Deco's clear message to Christensen According to Diario SPORT, Barcelona, led by sporting director Deco, has sent a clear message to Christensen: renewal is off the table, and the door is open if he chooses to leave. Deco has already tied down most of the squad to long-term contracts as part of his ongoing renewal project. Jules Kounde, Eric Garcia, and even Frenkie de Jong are set for new extensions next week. The only outlier is Christensen, whose deal expires in 2026, with no extension talks planned. Andreas Christensen has no intention to leave (Photo by) Barcelona are reportedly open to selling the Danish international, who is on a relatively high salary and spent much of last season injured. With an overbooking of centre-backs in the squad, Deco is focused on trimming the wage bill and building a younger, more sustainable core. However, the 28-year-old has no intention of walking away. Much like his exit from Chelsea, Christensen is prepared to stay until the end of his contract. Despite interest from Saudi Arabia and the Premier League, he has refused to even engage in negotiations. Convincing the Dane, therefore, will be one of Deco's priorities in the month of August.
Yahoo
4 days ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
4 days ago
- Bloomberg
Novo Nordisk Loses Spot Among Europe's 10 Most Valuable Firms
By Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe's most valuable public company again. Now, the stock — which is set for its worst week on record — is out of the top ten. The shares have plunged 33% this week after the maker of Ozempic and Wegovy cut its forecasts for the year and named a company insider as its new chief executive officer. The stock was also hit on Friday after US President Donald Trump demanded that pharmaceutical companies lower US drug prices.